Cystic fibrosis lung microbiome: Opportunities to reconsider management of airway infection

Pediatric Pulmonology

Volumn 50, Issue , 2015, Pages S31-S38

  Caverly, Lindsay J ^a   Zhao, Jiangchao ^a   LiPuma, John J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

airway bacterial community; cystic fibrosis; microbiome; microbiota

Indexed keywords

ACHROMOBACTER; AGE; ANAEROBIC BACTERIUM; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; COMMUNITY DYNAMICS; COMMUNITY STRUCTURE; CYSTIC FIBROSIS; DISEASE EXACERBATION; FUSOBACTERIUM; HUMAN; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MICROBIOME; NONHUMAN; PREVOTELLA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW; SPUTUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; VEILLONELLA; ANTIBIOTIC RESISTANCE; BACTERIUM; LUNG; METAGENOME; MICROBIOLOGY; MICROFLORA; RESPIRATORY TRACT INFECTIONS;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; BACTERIA; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; LUNG; METAGENOME; MICROBIOTA; RESPIRATORY TRACT INFECTIONS;

EID: 84941086226     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.23243     Document Type: Review

References (69)

1. Andersen D,. Cystic fibrosis of the pancrease and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 1938; 56: 344-399.
2. Rogers GB, Hart CA, Mason JR, Hughes M, Walshaw MJ, Bruce KD,. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2003; 41: 3548-3558.
3. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD,. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 2004; 42: 5176-5183.
4. van Belkum A, Renders NH, Smith S, Overbeek SE, Verbrugh HA,. Comparison of conventional and molecular methods for the detection of bacterial pathogens in sputum samples from cystic fibrosis patients. FEMS Immunol Med Microbiol 2000; 27: 51-57.
5. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR,. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 2007; 104: 20529-20533.
6. Bittar F, Richet H, Dubus JC, Reynaud-Gaubert M, Stremler N, Sarles J, Raoult D, Rolain JM,. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 2008; 3: e2908.
7. Cystic Fibrosis Foundation Patient Registry. 2013 Annual Data Report to the Center Directors. Bethesda, Maryland.
8. Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML, Moore JH, Guill MF, Morrison HG, Sogin ML,. et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 2012; 3: e00251-12.
9. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U, Andersen GL, Brown R, Fujimura KE,. et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE 2010; 5: e11044.
10. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, VanDevanter DR, Murray S, Li JZ,. et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 2012; 109: 5809-5814.
11. Stokell JR, Gharaibeh RZ, Hamp TJ, Zapata MJ, Fodor AA, Steck TR,. Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period. J Clin Microbiol 2015; 53: 237-247.
12. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman L, Daniels TW, Patel N, Forbes B,. et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax 2012; 67: 867-873.
13. Fodor AA, Klem ER, Gilpin DF, Elborn JS, Boucher RC, Tunney MM, Wolfgang MC,. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE 2012; 7: e45001.
14. Carmody LA, Zhao J, Schloss PD, Petrosino JF, Murray S, Young VB, Li JZ, LiPuma JJ,. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc 2013; 10: 179-187.
15. Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, Zhang Y, Surendra A, Gong Y, Elizabeth Tullis D, et al., Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep 2015; 5: 10241.
16. Rudkjobing VB, Thomsen TR, Alhede M, Kragh KN, Nielsen PH, Johansen UR, Givskov M, Hoiby N, Bjarnsholt T,. True microbiota involved in chronic lung infection of cystic fibrosis patients found by culturing and 16S rRNA gene analysis. J Clin Microbiol 2011; 49: 4352-4355.
17. Goddard AF, Staudinger BJ, Dowd SE, Joshi-Datar A, Wolcott RD, Aitken ML, Fligner CL, Singh PK,. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci USA 2012; 109: 13769-13774.
18. Rudkjobing VB, Thomsen TR, Alhede M, Kragh KN, Nielsen PH, Johansen UR, Givskov M, Hoiby N, Bjarnsholt T,. The microorganisms in chronically infected end-stage and non-end-stage cystic fibrosis patients. FEMS Immunol Med Microbiol 2012; 65: 236-244.
19. Delhaes L, Monchy S, Frealle E, Hubans C, Salleron J, Leroy S, Prevotat A, Wallet F, Wallaert B, Dei-Cas E,. et al. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management. PLoS ONE 2012; 7: e36313.
20. VanDevanter DR, LiPuma JJ,. Microbial diversity in the cystic fibrosis airways: where is thy sting? Future Microbiol 2012; 7: 801-803.
21. Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH,. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011; 46: 393-400.
22. Goss CH, Burns JL,. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007; 62: 360-367.
23. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW,. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002; 121: 64-72.
24. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC,. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-352.
25. Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP, Hoffman LR, Jones G, Allen CE, Patel N,. et al. Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros 2011; 10: 357-365.
26. Carmody LA, Zhao J, Kalikin LM, LeBar W, Simon RH, Venkataraman A, Schmidt TM, Abdo Z, Schloss PD, LiPuma JJ,. The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation. Microbiome 2015; 3: 12.
27. Price KE, Hampton TH, Gifford AH, Dolben EL, Hogan DA, Morrison HG, Sogin ML, O'Toole GA,. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome 2013; 1: 27.
28. Zemanick ET, Wagner BD, Harris JK, Wagener JS, Accurso FJ, Sagel SD,. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatr Pulmonol 2010; 45: 569-577.
29. Willger SD, Grim SL, Dolben EL, Shipunova A, Hampton TH, Morrison HG, Filkins LM, O'Toole GA, Moulton LA, Ashare A,. et al. Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosis. Microbiome 2014; 2: 40.
30. Smith DJ, Badrick AC, Zakrzewski M, Krause L, Bell SC, Anderson GJ, Reid DW,. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics. Eur Respir J 2014; 44: 922-930.
31. Tunney MM, Klem ER, Fodor AA, Gilpin DF, Moriarty TF, McGrath SJ, Muhlebach MS, Boucher RC, Cardwell C, Doering G,. et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax 2011; 66: 579-584.
32. Deschaght P, Schelstraete P, Van Simaey L, Vanderkercken M, Raman A, Mahieu L, Van Daele S, De Baets F, Vaneechoutte M,. Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load? PLoS ONE 2013; 8: e79010.
33. Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW, Knapp AA, Lory S, Brodie EL, Lynch SV, Bohannan BJ,. et al. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 2010; 12: 1293-1303.
34. Zhao J, Murray S, LiPuma JJ,. Modeling the impact of antibiotic exposure on human microbiota. Sci Rep 2014; 4: 4345.
35. Brook I, Fink R,. Transtracheal aspiration in pulmonary infection in children with cystic fibrosis. Eur J Respir Dis 1983; 64: 51-57.
36. Thomassen MJ, Klinger JD, Badger SJ, van Heeckeren DW, Stern RC,. Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis. J Pediatr 1984; 104: 352-356.
37. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A,. et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 995-1001.
38. Zemanick ET, Wagner BD, Sagel SD, Stevens MJ, Accurso FJ, Harris JK,. Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimens. PLoS ONE 2010; 5: e15101.
39. Sibley CD, Grinwis ME, Field TR, Eshaghurshan CS, Faria MM, Dowd SE, Parkins MD, Rabin HR, Surette MG,. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS ONE 2011; 6: e22702.
40. Worlitzsch D, Rintelen C, Bohm K, Wollschlager B, Merkel N, Borneff-Lipp M, Doring G,. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009; 15: 454-460.
41. Maughan H, Wang PW, Diaz Caballero J, Fung P, Gong Y, Donaldson SL, Yuan L, Keshavjee S, Zhang Y, Yau YC, et al., Analysis of the cystic fibrosis lung microbiota via serial Illumina sequencing of bacterial 16S rRNA hypervariable regions. PLoS ONE 2012; 7: e45791.
42. Brown PS, Pope CE, Marsh RL, Qin X, McNamara S, Gibson R, Burns JL, Deutsch G, Hoffman LR,. Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota. Ann Am Thorac Soc 2014; 11: 1049-1055.
43. Quinn RA, Lim YW, Maughan H, Conrad D, Rohwer F, Whiteson KL,. Biogeochemical forces shape the composition and physiology of polymicrobial communities in the cystic fibrosis lung. MBio 2014; 5: e00956-e00913.
44. Zemanick ET, Harris JK, Wagner BD, Robertson CE, Sagel SD, Stevens MJ, Accurso FJ, Laguna TA,. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS ONE 2013; 8: e62917.
45. Lim YW, Evangelista JS, 3rd, Schmieder R, Bailey B, Haynes M, Furlan M, Maughan H, Edwards R, Rohwer F, Conrad D,. Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. J Clin Microbiol 2014; 52: 425-437.
46. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG,. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 2008; 105: 15070-15075.
47. Quinn RA, Whiteson K, Lim YW, Salamon P, Bailey B, Mienardi S, Sanchez SE, Blake D, Conrad D, Rohwer F,. A Winogradsky-based culture system shows an association between microbial fermentation and cystic fibrosis exacerbation. ISME J 2015; 9: 1052.
48. Venkataraman A, Bassis CM, Beck JM, Young VB, Curtis JL, Huffnagle GB, Schmidt TM,. Application of a neutral community model to assess structuring of the human lung microbiome. MBio 2015; 6: e02284-14.
49. Bassis CM, Erb-Downward JR, Dickson RP, Freeman CM, Schmidt TM, Young VB, Beck JM, Curtis JL, Huffnagle GB,. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. MBio 2015; 6: e00037-15.
50. Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, Folkesson A, Jarmer HO, Aanaes K, von Buchwald C,. et al. Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 2012; 6: 31-45.
51. Whiteson KL, Bailey B, Bergkessel M, Conrad D, Delhaes L, Felts B, Harris JK, Hunter R, Lim YW, Maughan H,. et al. The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeography. Am J Respir Crit Care Med 2014; 189: 1309-1315.
52. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Kehagia V, Connett GJ, Bruce KD,. Use of 16S rRNA gene profiling by terminal restriction fragment length polymorphism analysis to compare bacterial communities in sputum and mouthwash samples from patients with cystic fibrosis. J Clin Microbiol 2006; 44: 2601-2604.
53. Zemanick ET, Wagner BD, Robertson CE, Stevens MJ, Szefler SJ, Accurso FJ, Sagel SD, Harris JK,. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc 2015; 12: 221-229.
54. Filkins LM, Hampton TH, Gifford AH, Gross MJ, Hogan DA, Sogin ML, Morrison HG, Paster BJ, O'Toole GA,. Prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J Bacteriol 2012; 194: 4709-4717.
55. Whiteson KL, Meinardi S, Lim YW, Schmieder R, Maughan H, Quinn R, Blake DR, Conrad D, Rohwer F,. Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. ISME J 2014; 8: 1247-1258.
56. Guss AM, Roeselers G, Newton IL, Young CR, Klepac-Ceraj V, Lory S, Cavanaugh CM,. Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 2011; 5: 20-29.
57. Hampton TH, Green DM, Cutting GR, Morrison HG, Sogin ML, Gifford AH, Stanton BA, O'Toole GA,. The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention. Microbiome 2014; 2: 14.
58. Lim YW, Schmieder R, Haynes M, Furlan M, Matthews TD, Whiteson K, Poole SJ, Hayes CS, Low DA, Maughan H,. And others. Mechanistic model of Rothia mucilaginosa adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic data. PLoS ONE 2013; 8: e64285.
59. Lim YW, Schmieder R, Haynes M, Willner D, Furlan M, Youle M, Abbott K, Edwards R, Evangelista J, Conrad D,. And others. Metagenomics and metatranscriptomics: windows on CF-associated viral and microbial communities. J Cyst Fibros 2013; 12: 154-164.
60. Zhao J, Carmody LA, Kalikin LM, Li J, Petrosino JF, Schloss PD, Young VB, LiPuma JJ,. Impact of enhanced Staphylococcus DNA extraction on microbial community measures in cystic fibrosis sputum. PLoS ONE 2012; 7: e33127.
61. Zhao J, Evans CR, Carmody LA, LiPuma JJ,. Impact of storage conditions on metabolite profiles of sputum samples from persons with cystic fibrosis. J Cyst Fibros 2015, http://dx.doi.org/10.1016/j.jcf.2015.02.004
62. Cuthbertson L, Rogers GB, Walker AW, Oliver A, Hoffman LR, Carroll MP, Parkhill J, Bruce KD, van der Gast CJ,. Implications of multiple freeze-thawing on respiratory samples for culture-independent analyses. J Cyst Fibros 2014, http://dx.doi.org/10.1016/j.jcf.2014.10.004
63. Rogers GB, Cuthbertson L, Hoffman LR, Wing PA, Pope C, Hooftman DA, Lilley AK, Oliver A, Carroll MP, Bruce KD,. et al. Reducing bias in bacterial community analysis of lower respiratory infections. ISME J 2013; 7: 697-706.
64. Rogers GB, Marsh P, Stressmann AF, Allen CE, Daniels TV, Carroll MP, Bruce KD,. The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples. Clin Microbiol Infect 2010; 16: 1656-1658.
65. Rogers GB, Stressmann FA, Koller G, Daniels T, Carroll MP, Bruce KD,. Assessing the diagnostic importance of nonviable bacterial cells in respiratory infections. Diagn Microbiol Infect Dis 2008; 62: 133-141.
66. Boutin S, Graeber SY, Weitnauer M, Panitz J, Stahl M, Clausznitzer D, Kaderali L, Einarsson G, Tunney MM, Elborn JS,. et al. Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis. PLoS ONE 2015; 10: e0116029.
67. Chiao TH, Clancy TM, Pinto A, Xi C, Raskin L,. Differential resistance of drinking water bacterial populations to monochloramine disinfection. Environ Sci Technol 2014; 48: 4038-4047.
68. Lisle JT, Pyle BH, McFeters GA,. The use of multiple indices of physiological activity to access viability in chlorine disinfected Escherichia coli O157: H7. Lett Appl Microbiol 1999; 29: 42-47.
69. Wahman DG, Wulfeck-Kleier KA, Pressman JG,. Monochloramine disinfection kinetics of Nitrosomonas europaea by propidium monoazide quantitative PCR and Live/dead BacLight methods. Appl Environ Microbiol 2009; 75: 5555-5562.